Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical | Latest News RSS feed

Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical - Latest News


ADC Therapeutics SA: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been ... read more

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The trial will enroll approximately 140 patients with relapsed or refractory DLBCL at multiple centers in the USA and Europe. “We are pleased to have dosed the first patient in our registrational Phas... read more

BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours

ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics ... (BGBIO.OL), announces that the first patient has been dosed in a phase I clinical trial ... read more

Looking for another news?


ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

The first stage is a dose escalation phase which will recruit up to 30 patients ... clinical trials, with a deep pipeline of other ADCs in preclinical development. More information regarding these tri... read more


First patient dosed in latest ADC trial of camidanlumab tesirine

(Sharecast News) - Oncology drug discovery and development company ADC Therapeutics announced on Friday that the first patient had been ... % complete response rate, at the dose being considered for a ... read more

EQS-News: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADCT-601 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors (NCT03700294). About ADC Therapeutics ADC Therapeutics SA ... from first in human to pivotal Phase ... read more

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia

The first stage (Phase Ia) is a dose escalation ... Ia/Ib clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute ly... read more

BerGenBio begins phase I trial of ADCT-601, a novel anti-AXL ADC in patients with advanced solid tumours

BerGenBio ASA announces that the first patient has been dosed in a phase I clinical trial evaluating the safety ... BGB601 was out-licensed for ADC development to ADC Therapeutics SA (ADCT). In precli... read more

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for Its Second Novel Antibody Drug Conjugate ADCT-402 against Lymphomas and Leukemia

LAUSANNE, Switzerland & LONDON & MURRAY HILL, N.J.--(BUSINESS WIRE)--ADC Therapeutics SA (ADCT ... single doses, and it outperformed other CD19 targeted ADCs currently in clinical development. The fir... read more

EQS-News: ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

Lausanne, Switzerland, January 4, 2019 - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us